Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 5/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460199 | 0.86 | PARP10 (0.45) | MRGPRX4DHODHNR4A2SIRT2SPHK2 | |
| SCHEMBL2459477 | 0.86 | MRGPRX4 (0.43) | MRGPRX4DHODHNR4A2SIRT2SPHK2 | |
| SCHEMBL3537072 | 0.86 | MAOB (0.40) | MRGPRX4DHODHNR4A2MAOB | |
| SCHEMBL2460398 | 0.85 | MAOB (0.41) | MRGPRX4DHODHNR4A2MAOB | |
| SCHEMBL2457734 | 0.83 | NR1H2 (0.41) | MRGPRX4MAOB | |
| SCHEMBL2459807 | 0.82 | IGF1R (0.47) | MRGPRX4DHODHNR4A2SPHK2SPHK1 | |
| SCHEMBL2457017 | 0.82 | MAOB (0.39) | MRGPRX4DHODHMAOB | |
| SCHEMBL2458332 | 0.82 | NR1H2 (0.39) | MRGPRX4DHODHMAOB | |
| SCHEMBL2459704 | 0.82 | TSHR (0.39) | MRGPRX4DHODHNR4A2MAOB | |
| SCHEMBL2460551 | 0.81 | IGF1R (0.48) | MRGPRX4SPHK2SPHK1JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957496-B1 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7648987-B2 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1957496-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | MRGPRX4 356/4885DHODH 3662/4885NR4A2 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.